Loading...
Market
How will Novo Nordisk's stock price react within one week of Phase 3 trial results for Liraglutide (Victoza) in Alzheimer's treatment?
2
Resolution / Starting Odds
Stock price increases by 10% or more • 25%
Stock price decreases by 10% or more • 25%
Stock price remains within 10% of current value • 25%
Stock price fluctuates but no clear trend • 25%
Stock market data and financial news outlets
Story
Novo Nordisk's GLP-1 Drug Liraglutide (Victoza) Shows Potential in Slowing Alzheimer's Progression
Jul 30, 2024, 11:14 AM
Novo Nordisk's older GLP-1 drug, liraglutide, commonly used for managing diabetes and weight loss, appears to slow cognitive decline in Alzheimer's patients. According to Phase 2b clinical trial data presented at the Alzheimer's Association International Conference 2024, the drug may protect the brain and slow disease progression. The study, published on Tuesday, showed that liraglutide, known commercially as Victoza, yielded mixed results in a small mid-stage study but indicated a potential to slow the loss of brain volume in people with mild Alzheimer's disease.
View original story
Similar markets
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No significant change or decrease • 25%
Increase by over 10% • 25%
Increase by 5-10% • 25%
No significant change • 25%
Decrease • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increases by more than 10% • 25%
Increases by 5-10% • 25%
Changes by less than 5% • 25%
Decreases • 25%
Both stocks increase • 25%
Both stocks decrease • 25%
One increases, one decreases • 25%
No significant change • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Increase by more than 5% • 25%
Change within +/- 5% • 25%
Decrease by 5-10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
